Non-Small Cell Lung Cancer (NSCLC) Clinical Trials (2026): 1,046 Recruiting Interventional Studies

Last updated: April 2, 2026

Current Clinical Trial Landscape

Recruiting Trials by Biomarker

EGFR-Mutated (187 trials)

Osimertinib is standard first-line. Key frontiers: combination strategies, adjuvant expansion, and post-osimertinib options:

• First-line combinations:
  • NCT06970639 - Furmonertinib + Chemo vs Osimertinib (Phase 3)
  • NCT06674343 - Furmonertinib 160mg first-line for EGFR classical mutations (Phase 3)
  • NCT07183189 - SHR-A2009 + Aumolertinib vs Aumolertinib first-line (Phase 3)
  • NCT06734391 - JMT101 + Osimertinib vs Osimertinib first-line (Phase 3)
• After osimertinib progression (MET amplification):
  • NCT05261399 - Savolitinib + Osimertinib vs Chemo (Phase 3, MET-amplified)
• After osimertinib (ADC-based):
  • NCT06350097 - Osimertinib ± Datopotamab Deruxtecan first-line (Phase 3)
  • NCT06416814 - Dato-DXd ± Osimertinib vs Chemo after EGFR TKI (Phase 3)
  • NCT06305754 - Sacituzumab Tirumotecan vs Pemetrexed/Carboplatin after EGFR TKI (Phase 3)
  • NCT06927986 - SYS6010 (ADC) vs Chemo for EGFR-mutated NSCLC (Phase 3)
• EGFR exon 20 insertion:
  • NCT06452277 - Sevabertinib vs SOC (Phase 3)
  • NCT07128199 - Zipalertinib adjuvant (Phase 3)
  • NCT07182682 - Sunvozertinib adjuvant in early-stage NSCLC with EGFR ex20ins (Phase 3)
• Adjuvant:
  • NCT04853342 - Furmonertinib adjuvant vs Placebo (Phase 3)
  • NCT06041776 - Befotertinib adjuvant in stage IB-IIIB (Phase 3)

KRAS G12C-Mutated (66 trials)

Sotorasib and adagrasib are approved. Next-gen inhibitors and combinations are the frontier:

• First-line combinations:
  • NCT05920356 - Sotorasib + Chemo vs Pembrolizumab + Chemo first-line (Phase 3)
  • NCT06119581 - Olomorasib + Pembrolizumab ± Chemo first-line (Phase 3)
  • NCT06416410 - JAB-21822 + JAB-3312 (SHP2i) vs SOC first-line (Phase 3)
  • NCT07174908 - IN10018 (FAKi) + D-1553 vs SOC first-line non-squamous (Phase 3)
• Pretreated:
  • NCT04613596 - Adagrasib ± Pembrolizumab (Phase 2/3)
  • NCT06300177 - D-1553 vs Docetaxel (Phase 3)
• RAS multi-selective (pan-KRAS):
  • NCT06881784 - Daraxonrasib (RMC-6236) in RAS-mutated NSCLC (Phase 3, RASolve 301)
• Adjuvant:
  • NCT07431827 - Pembrolizumab ± Calderasib (MK-1084) adjuvant in resected KRAS G12C (Phase 3)
  • NCT06890598 - Olomorasib + SOC in resected/unresectable KRAS G12C (Phase 3)

ALK-Rearranged (37 trials)

Lorlatinib is standard first-line. Research focuses on resistance mechanisms and adjuvant use.

ROS1-Rearranged (20 trials)

• NCT06564324 - Taletrectinib vs SOC in ROS1+ advanced NSCLC (Phase 3)
• NCT07154706 - TRUST-IV: Taletrectinib adjuvant in ROS1+ NSCLC (Phase 3)

Other Targetable Mutations

• HER2-mutant (43 trials):
  • NCT07178795 - BL-M07D1 (ADC) vs Pembrolizumab + Chemo first-line HER2-mutant (Phase 3)
  • NCT06899126 - T-DXd + Pembrolizumab + Chemo first-line HER2-overexpressing (Phase 3)
  • NCT06151574 - Beamion LUNG-2: Zongertinib in HER2-mutant NSCLC (Phase 3)
• MET (31 trials): Savolitinib, tepotinib, capmatinib for MET exon 14 skipping and MET amplification
• RET (8 trials): Selpercatinib approved; NCT06031558 - SY-5007 (next-gen RET inhibitor) in RET fusion+ NSCLC (Phase 3)
• BRAF V600E (6 trials): NCT05768178 - DETERMINE: Vemurafenib + Cobimetinib in BRAF+ cancers (Phase 3)

No Targetable Mutation (Immunotherapy-Based)

For patients without actionable driver mutations, checkpoint immunotherapy ± chemotherapy is standard. Novel approaches:

• First-line:
  • NCT06868277 - Rilvegostomig (PD-1/TIGIT bispecific) or Pembrolizumab monotherapy, PD-L1-high (Phase 3)
  • NCT06692738 - Rilvegostomig or Pembrolizumab + Chemo for squamous NSCLC (Phase 3)
  • NCT06357533 - Dato-DXd + Rilvegostomig first-line non-squamous (Phase 3)
  • NCT05215340 - Dato-DXd + Pembrolizumab vs Pembrolizumab first-line (Phase 3)
  • NCT06170788 - Sacituzumab Tirumotecan + Pembrolizumab vs Pembrolizumab (Phase 3)
• Pretreated / second-line:
  • NCT06074588 - Sacituzumab Tirumotecan vs Chemo, non-squamous (Phase 3)
  • NCT07291037 - Datopotamab Deruxtecan vs Docetaxel, TROP2+ (Phase 3)
  • NCT07144280 - PF-08046054/SGN-PDL1V (ADC) vs Docetaxel (Phase 3)
  • NCT06616584 - Cemiplimab added to chemo after prior IO (Phase 3)
• Stage III unresectable (consolidation):
  • NCT05211895 - Durvalumab + Domvanalimab after chemoradiation (Phase 3)
  • NCT07361497 - Pumitamig vs Durvalumab after chemoradiation (Phase 3)
  • NCT06216301 - LUNAR-2: TTFields + Pembrolizumab + Chemo for metastatic NSCLC (Phase 3)
• Adjuvant / perioperative:
  • NCT05487391 - QL1706 (PD-1/CTLA-4 bispecific) + Chemo adjuvant stage II-IIIB (Phase 3)
  • NCT07222566 - PF-08634404 + Chemo for locally advanced squamous (Phase 3)

Novel Approaches

• ADCs (85 trials): Datopotamab deruxtecan, sacituzumab tirumotecan, sigvotatug vedotin (PD-L1-targeted ADC), SYS6010 — transforming both first-line and later-line treatment
• Bispecific antibodies (55 trials): Rilvegostomig (PD-1/TIGIT), ivonescimab (PD-1/VEGF), cadonilimab (PD-1/CTLA-4) — next-gen checkpoint blockade
• Pan-RAS inhibitors: Daraxonrasib (RMC-6236) — first RAS multi-selective agent, targeting KRAS G12C/G12D/G12V/G13D and other RAS mutations
• Tumor treating fields: TTFields + immunotherapy (LUNAR-2) — non-systemic approach for metastatic NSCLC

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Frequently Asked Questions